Development of CXCR1/2 BsAb for the treatment of solid tumors

This study focused on countering immune evasion in cancer treatment by targeting myeloid-derived suppressor cells (MDSCs) using a novel bispecific antibody against CXCR1 and CXCR2 receptors. The research involved developing the antibody, confirming its accuracy and reactivity, and testing its inhibitory effect on MDSC recruitment. In mouse models, the antibody was combined with an anti-PD1 antibody in two tumor types. In triple-negative breast cancer, a significant decrease in tumor size was observed alongside reduced MDSCs, leading to improved T cell infiltration. This study offers a promising strategy to enhance cancer immunotherapy by reshaping the tumor microenvironment.